The efficacy and safety of cannabidiol as adjunct treatment for drug‐resistant idiopathic epilepsy in 51 dogs: A double‐blinded crossover study

Abstract Background: Approximately 30% of dogs with idiopathic epilepsy (IE) are drug‐resistant. Recent studies have suggested cannabidiol (CBD) may be an effective anticonvulsant in dogs with IE. Objective: To evaluate the addition of CBD to antiseizure drugs (ASDs) on seizure frequency and to report adverse events in dogs with drug‐resistant IE. Animals: Fifty‐one dogs. Dogs having at least 2 seizures per month while receiving at least 1 ASD were included in the trial. Methods: Double‐blinded placebo‐controlled crossover study. The 5